logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial | Journal Article / Research | MSF Science Portal
Journal Article
|Research

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial

Hailu ADE, Musa AM, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil EAG, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge SM, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith PJ, Muthami L, Royce C, Ellis SJ, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is increasing. Improved treatment options are needed. Paromomycin was shown to be an efficacious first-line treatment with low toxicity in India.

Countries

Ethiopia Kenya Sudan

Subject Area

neglected tropical diseaseskala azar

Languages

English
DOI
10.1371/journal.pntd.0000709
Published Date
26 Oct 2010
PubMed ID
21049059
Journal
PLOS Neglected Tropical Diseases
Volume | Issue | Pages
Volume 4, Issue 10
Issue Date
2010-10-26
Dimensions Badge